CELL INTELLIGENCE · 肿瘤细胞治疗研究

Cutaneous squamous cell carcinoma (cSCC) can present as advanced disease requiring systemic therapy. Programmed cell death-1 (PD-1) inhibitors such as cemiplimab enable significant tumor regression. We report a patient with advanced cSCC who achieved near-complete remission after cemiplimab, followed by Mohs surgery revealing unexpected frontal sinus communication. This case underscores the importance of considering underlying structural changes when operating in previously treated areas. PD-1 inhibitors such as cemiplimab can induce dramatic regression of advanced cutaneous squamous cell carcinoma through immune-mediated tumor clearance.Immunotherapy may mask underlying tumor-related structural damage, leading to unexpected intraoperative findings during Mohs surgery.Preoperative imaging and multidisciplinary coordination should be considered in patients with prior PD-1 therapy, especially in high-risk anatomic locations.